Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996508 | 0.83 | HSD17B10 (0.45) | KMT2AMEN1PPARGNCOA2NCOA1 | |
| SCHEMBL30716878 | 0.83 | RAB9A (0.51) | ALDH1A1CYP1A2PAK4HSD17B10RAB9A | |
| SCHEMBL4152240 | 0.83 | RAB9A (0.51) | ALDH1A1CYP1A2PAK4HSD17B10RAB9A | |
| SCHEMBL1620981 | 0.80 | PAK4 (0.49) | ALDH1A1CYP1A2PAK4HTTHSD17B10 | |
| SCHEMBL3002685 | 0.80 | METAP2 (0.50) | PPARGHSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27158283 | 0.78 | CXCR2 (0.43) | KMT2AMEN1PPARGALDH1A1HPGD | |
| SCHEMBL741057 | 0.78 | PIN1 (0.56) | KMT2AMEN1PPARGNCOA2NCOA1 | |
| SCHEMBL30657791 | 0.75 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1HPGDRAB9A | |
| Chloroform SCHEMBL743258 | 0.75 | PIN1 (0.53) | KMT2AMEN1PPARGNCOA2NCOA1 | |
| SCHEMBL8369493 | 0.74 | CDK1 (0.44) | CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173173-B1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2013-07-24 | — | — | EP | disclosed |
| US-8222260-B2 | Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives | Univerzita Palackego V Olomouci (CZ) | 2012-07-17 | — | — | US | disclosed |
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-0896063-B9 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| EP-2173173-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-04-14 | — | — | EP | disclosed |
| EP-0896063-B1 | Method for the selection of genetically transformed cells and compounds for use in the method | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009003428-A2 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-01-08 | — | — | WO | disclosed |
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0601092-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | Novartis AG (CH) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993005163-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | DPYD, XDH, APRT | KMT2A 2219/4885MEN1 3890/4885PPARG 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.